SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
1.31 (USD) • At close April 17, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 1 | 7.6 | 1.9 | 0 | 0 | 0 | 0 | 0 | 9.319 | 2.487 | 2.038 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0.1 | 0.2 | 0 | 0 | 0 | 0 | 0.003 | 0.355 | 1.403 | 0.52 | 0 | 20.787 | 0 | 0 | 0 | 11.413 | 0 |
| Gross Profit
| 0 | 0 | 0.9 | 7.4 | 1.9 | 0 | 0 | 0 | -0.003 | -0.355 | 7.916 | 1.967 | 2.038 | -20.787 | 0 | 0 | 0 | -11.413 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.9 | 0.974 | 1 | 0 | 0 | 0 | 0 | 0 | 0.849 | 0.791 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 19.096 | 24.007 | 30.268 | 21.374 | 9.282 | 7.285 | 18.317 | 6.067 | 19.86 | 23.611 | 28.354 | 21.076 | 14.614 | 11.538 | 7.873 | 8.892 | 7.054 | 6.747 | 1.298 |
| General & Administrative Expenses
| 12.417 | 13.862 | 12.582 | 11.32 | 9.6 | 9.923 | 12.772 | 15.089 | 12.007 | 10.609 | 31.344 | 14.6 | 6.585 | 6.863 | 8.752 | 8.628 | 4.874 | 3.735 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.386 | 0 | 0 | 2.625 | 0.931 | 0 |
| SG&A
| 12.417 | 13.862 | 12.582 | 11.32 | 9.6 | 9.923 | 12.772 | 15.089 | 12.007 | 10.609 | 31.344 | 14.6 | 6.585 | 9.249 | 8.752 | 8.628 | 7.499 | 4.666 | 0.633 |
| Other Expenses
| 0 | 0 | 10 | 5.7 | 0 | 0 | -3.032 | 0 | 0 | 0.509 | 0.17 | 0.037 | -13.178 | 9.249 | 0 | 0 | 7.499 | 0 | 0 |
| Operating Expenses
| 31.513 | 37.869 | 42.85 | 32.694 | 18.882 | 17.208 | 31.089 | 21.156 | 31.867 | 34.22 | 60.138 | 35.807 | 21.199 | 20.787 | 16.625 | 17.52 | 14.553 | 11.413 | 2.405 |
| Operating Income
| -31.513 | -37.869 | -41.95 | -25.294 | -16.982 | -20.041 | -31.089 | -23.039 | -31.867 | -34.22 | -52.222 | -33.84 | -21.199 | -20.787 | -16.625 | -17.52 | -14.553 | -11.413 | -2.405 |
| Operating Income Ratio
| 0 | 0 | -41.95 | -3.328 | -8.938 | 0 | 0 | 0 | 0 | 0 | -5.604 | -13.607 | -10.402 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.632 | 0.529 | 0.649 | 4.358 | 0.208 | 0.668 | 2.541 | -7.787 | 5.13 | -4.371 | 13.616 | -41.786 | -13.178 | 9.302 | 4.632 | -0.867 | 0.18 | 0.448 | 0 |
| Income Before Tax
| -30.881 | -37.34 | -41.301 | -20.936 | -16.774 | -19.373 | -29.048 | -23.501 | -10.858 | -38.591 | -36.606 | -75.626 | -34.377 | -11.485 | -11.993 | -18.387 | -14.373 | -10.965 | -2.405 |
| Income Before Tax Ratio
| 0 | 0 | -41.301 | -2.755 | -8.828 | 0 | 0 | 0 | 0 | 0 | -3.928 | -30.409 | -16.868 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.649 | -0.237 | -0.017 | -0.081 | -1.378 | 0.253 | 0.243 | 0.365 | -15.446 | 1.052 | -1.052 | -9.302 | -4.632 | 0.867 | 0 | 0.025 | 0 |
| Net Income
| -30.881 | -37.34 | -40.652 | -20.699 | -16.757 | -19.292 | -27.67 | -23.754 | -23.549 | -63.902 | -36.606 | -76.678 | -34.969 | -11.485 | -11.993 | -18.387 | -14.373 | -10.99 | -2.405 |
| Net Income Ratio
| 0 | 0 | -40.652 | -2.724 | -8.819 | 0 | 0 | 0 | 0 | 0 | -3.928 | -30.832 | -17.158 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.051 | -0.15 | -0.23 | -0.15 | -0.23 | -0.84 | -11.76 | -56.39 | -394.12 | -1,372.03 | -1,022.2 | -2,834.26 | -1,866.21 | -1,053.77 | -2,177.38 | -3,783.33 | -3,486.9 | -2,893.63 | -636.24 |
| EPS Diluted
| -0.051 | -0.15 | -0.23 | -0.15 | -0.23 | -0.84 | -11.76 | -56.39 | -394.12 | -1,372.02 | -1,022.2 | -2,834.26 | -1,866.21 | -1,053.77 | -2,177.38 | -3,783.33 | -3,486.9 | -2,893.63 | -636.24 |
| EBITDA
| -31.513 | 0.529 | -31.95 | -19.663 | -16.397 | 0.668 | 0 | -23.039 | -15.985 | -37.476 | -36.606 | 7.628 | -34.377 | -11.322 | -11.821 | -18.22 | -14.242 | -10.929 | -2.405 |
| EBITDA Ratio
| 0 | 0 | -31.95 | -2.587 | -8.63 | 0 | 0 | 0 | 0 | 0 | -3.928 | 3.067 | -16.868 | 0 | 0 | 0 | 0 | 0 | 0 |